

Contents

Chapter No.	Title	Page No.
1	Introduction	1-40
2	Aims and Objectives	41-42
3	Review of Related Literature	43-53
4	Experimental Set-up	54-57
5	Segregated drug delivery of two incompatible drugs : Rifampicin and Isoniazid	58-202
5.1	Quality by design enabled formulation development and optimization of enteric coated sustained release Isoniazid tablet	58-117
	5.1.1. Drug Profile	58-60
	5.1.2. Analytical Methods	61-72
	5.1.3. Methodology for drug product formulation development	73-81
	5.1.4. Results and Discussion	82-110
	5.1.5. Conclusion	111-111
	5.1.6. References	112-117
5.2	Quality by design enabled formulation development and optimization of enteric coated sustained release Isoniazid pellets	118-144
	5.2.1. Analytical Methods	118-118
	5.2.2. Methodology for drug product formulation development	118-125
	5.2.3. Results and Discussion	126-141
	5.2.4. Conclusion	142-142
	5.2.5. References	143-144
5.3	Quality by design enabled formulation development and optimization of floating sustained release Rifampicin tablet	145-199
	5.3.1. Drug Profile	145-147
	5.3.2. Analytical Methods	148-151
	5.3.3. Methodology for drug product formulation development	152-158
	5.3.4. Results and Discussion	159-192
	5.3.5. Conclusion	193-194
	5.3.6. References	195-199

5.4		Drug degradation study from fixed dose combination of Rifampicin and Isoniazid	200-202
	5.4.1.	Analytical Methods	200-200
	5.4.2.	<i>In vitro</i> drug degradation from novel dosage form	200-201
	5.4.3.	References	202
6		To protect the acid labile drug from acidic stomach environment and specifically targeting it's release in intestine: Lansoprazole	203-231
	6*	Preparation and characterization of spray dried Lansoprazole enteric microparticles	203-231
	6.1.	Drug Profile	203-204
	6.2.	Analytical Methods	205-212
	6.3.	Methodology for drug product formulation development	212-215
	6.4.	Results and Discussion	216-228
	6.5.	Conclusion	229-229
	6.6.	References	230-331
7		Prevent precipitation of weakly basic drug at intestinal pH: Dipyridamole	232-272
	7*	Preparation and characterization of diverse Dipyridamole formulations	232-272
	7.1.	Drug Profile	232-233
	7.2.	Analytical Methods	234-239
	7.3.	Methodology for drug product formulation development	239-247
	7.4.	Results and Discussion	247-268
	7.5.	Conclusion	269-269
	7.6.	References	270-272
8		Summary and Conclusion	273-283
9		Publications	284-284